A new study, involving LMB researchers and former LMB group leader, Sarah Teichmann, describes a fundamental mechanism regulating a protein’s shape and function, with potential applications in biotechnology and drug development. More…
‘Hairclip’ protein mechanism explained
Sjors Scheres named by Nature as one of ten people who mattered in 2014
LMB group leader Sjors Scheres is profiled by Nature as one of its ten people of the year, for his work on bringing the cell’s molecular machines into sharper focus, with the use of cryo-EM. More…
Heptares Therapeutics granted key patents for GPCR-Focused Drug Discovery Platform
Heptares Therapeutics, a leading G protein-coupled receptor (GPCR) structure-guided drug discovery company, has recently been granted multiple key patents in the USA. GPCRs are a superfamily of drug receptors linked to a wide range of human diseases and Heptares was founded in 2007 to develop and commercialise pioneering research from the LMB and the National Institute of Medical Research (NIMR) to find new medicines targeting GPCRs. Sir John Saville presented the inventors with a memento to mark the award of these key patents for the GPCR-focused drug discovery platform. More…
LMB’s Pat Edwards interviewed for the Long and Short magazine
Pat Edwards discusses her role in Research Support at the LMB and why the LMB is such a special place to work. This article is no longer available from the source website: TheLong+Short 2014
Synthetic enzymes hint at life without DNA or RNA
Enzymes that don’t exist in nature have been made from genetic material that doesn’t exist in nature either, called XNA, or xeno nucleic acid. New Scientist reports how the breakthrough from Philipp Holliger’s group at the LMB reinforces the possibility that life could evolve without DNA or RNA, the two self-replicating molecules considered indispensible for life on Earth. More…
Major synthetic life breakthrough as LMB scientists make the first artificial enzymes
For the first time ever, researchers have made synthetic enzymes – the vital ingredients needed for life – from artificial genetic material that does not exist outside the laboratory. This milestone from Philipp Holliger’s group at the LMB could soon lead to new ways of developing drugs and medical treatments, as reported in the Independent.